• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Basic Research of Novel Molecular Target on Cancer Chemotherapy

Research Project

Project/Area Number 14570122
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Pathological medical chemistry
Research InstitutionNagasaki University

Principal Investigator

GOTO Shinji  Nagasaki University, Graduate School of Biomedical Sciences, Research Associate, 大学院・医歯薬学総合研究科, 助手 (50186889)

Co-Investigator(Kenkyū-buntansha) KONDO Takahito  Nagasaki University, Graduate School of Biomedical Sciences, Professor, 大学院・医歯薬学総合研究科, 教授 (00158908)
IHARA Yoshito  Nagasaki University, Graduate School of Biomedical Sciences, Associate Professor, 大学院・医歯薬学総合研究科, 助教授 (70263241)
Project Period (FY) 2002 – 2003
Project Status Completed (Fiscal Year 2003)
Budget Amount *help
¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 2003: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2002: ¥1,600,000 (Direct Cost: ¥1,600,000)
Keywordsglutathione S-transferasen / drug resistance / nuclear translocation / cisplatin / doxorubicin / cancer / glutathione S-transferaseπ / drug resistance / doxorubicin / apoptosis
Research Abstract

Recent study has shown that nuclear glutathione S-transferase (GST)n accumulates in cancer cells resistant to doxorubicin hydrochloride (DOX) and may function to prevent nuclear DNA damage caused by DOX (Goto et al., FASEB J., 15, 2702-2714 (2001)). It is not clear if the amount of nuclear GSTn increases in response to other anti-cancer drugs and if so, what is the physiological significance of the nuclear transfer of GSTt in the acquisition of drug-resistance in cancer cells. In the 'present study, we employed three cancer cell lines, HCT8 human colonic cancer cells, A549 human lung adenocarcinoma cells, and T98G human glioblastoma cells. We. estimated the nuclear transfer of GSTn induced by the anti-cancer drugs cisplatin (CDDP), irinotecan hydrochloride (CPT 11), etoposide (VP-16) and 5-fluorouracil (5-FU). It was found that : (1) Nuclear GSTn accumulated in these cancer cells in response to CDDP, DOX, CPT 11, VP-16 and 5-FU. (2) An inhibitor of the nuclear transport of GSTn, edible mushroom lectin (Agaricus bisporus lectin, ABL), increased the sensitivity of the cancer cells to DOX and CDDP, and partially to CPT 11. Treatment with ABL had no apparent effect on the cytotoxicity of VP-16 and 5-FU. These results suggest that inhibitors of the nuclear transfer of GSTn have practical value in producing an increase of sensitivity to DOX, CDDP and CPT 11.

Report

(3 results)
  • 2003 Annual Research Report   Final Research Report Summary
  • 2002 Annual Research Report
  • Research Products

    (3 results)

All Other

All Publications (3 results)

  • [Publications] Shinji Goto: "Significance of nuclear glutathione S-transferase π in resistance to anti-cancer drugs."Japanese Journal of Cancer Research. 93. 1047-1056 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Shinji Goto, Kensaku Kamada, Youko Soh, Yoshito Ihara, Takahito Kondo: "Significance of nuclear glutathione S-transferaseπ in resistance to anti-cancer drugs."Japanese Journal of Cancer Research. 93. 1047-1056 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Shinji Goto: "Significance of Nuclear Glutathione S-Transferase π in Resistance to Anti-cancer Drugs"Japanese Journal of Cancer Research. 93. 1047-1056 (2002)

    • Related Report
      2002 Annual Research Report

URL: 

Published: 2002-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi